China Proposes Export Restrictions on Advanced Biopharmaceutical Technology
China's MOFCOM and MOST issued Announcement No. 48 of 2026 proposing new export controls on advanced biopharmaceutical technology, with immediate registration requirements affecting cross-border life sciences deals.
On October 16, 2026, China's Ministry of Commerce and Ministry of Science and Technology jointly issued Announcement No. 48 of 2026, a proposal adding new export restrictions on certain advanced biopharmaceutical technologies and imposing immediate registration requirements for transfers of the covered technology. The measure is at the proposal stage, and the specific technology catalogue, licensing pathways, and mechanics of the registration regime are not set out in the material reviewed here; counsel should confirm scope against the official text and any comment or implementation timetable before advising clients.
The development matters because Chinese biopharmaceutical technology underpins a growing share of cross-border licensing, co-development, and investment structures. Counterparties in China-domiciled licensing, option, and equity transactions may now face an added regulatory gate at signing rather than only at closing, affecting conditions precedent, long-stop dates, diligence sequencing, and allocation of regulatory risk in definitive agreements. Companies with platforms or pipelines touching the listed categories would also need to screen whether associated know-how, equipment, or materials fall within scope.
What to watch: the finalized Announcement text, the scope of the restricted technology categories and registration mechanics, any implementing guidance from MOFCOM and MOST, and how counterparties in pending and new deals restructure timelines to accommodate the regime. Scope details remain uncertain as reported here and should be verified.